Morepen LaboratoriesNSE:MOREPENLAB +2.89%79 5-Year Yield-on-Cost % is 0.34 as of Jul. 06, 2026, which is 29% below its 10-year median of 0.48. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 79/100 and a GF Value™ of ₹49.90 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 518 Drug Manufacturers companies, Morepen Laboratories ranks worse than 88.03% on this metric.
Morepen Laboratories's yield on cost for the quarter that ended in Mar. 2026 was 0.34.
The historical rank and industry rank for Morepen Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:MOREPENLAB'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.34 Med: 0.48 Max: 0.59
Current: 0.34
During the past 13 years, Morepen Laboratories's highest Yield on Cost was 0.59. The lowest was 0.34. And the median was 0.48.
NSE:MOREPENLAB's 5-Year Yield-on-Cost % is ranked worse than 88.03% of 518
companies
in the Drug Manufacturers industry
Industry Median: 2.265
vs NSE:MOREPENLAB: 0.34
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Morepen Laboratories 5-Year Yield-on-Cost % Related Terms
NSE:MOREPENLAB vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Morepen Laboratories (NSE:MOREPENLAB) has a 5-Year Yield-on-Cost % of 0.34 as of Jul. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Morepen Laboratories and its competitors. This is 29% below median its historical median of 0.48. Over the past decade, Morepen Laboratories' 5-Year Yield-on-Cost % has ranged from 0.34 to 0.59. According to the industry distribution chart, Morepen Laboratories ranks #456 out of 518 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Morepen Laboratories' 5-Year Yield-on-Cost % too high?
Morepen Laboratories' current 5-Year Yield-on-Cost % of 0.34 is 29% below median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.59. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. Morepen Laboratories' value of 0.34 is 85% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #456 out of 518 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Morepen Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #456 out of 518 companies for 5-Year Yield-on-Cost %. This places Morepen Laboratories in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.27. Morepen Laboratories' value of 0.34 is 85% below this benchmark. Historically, Morepen Laboratories' own 5-Year Yield-on-Cost % has ranged from 0.34 to 0.59 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 2.27, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 5-Year Yield-on-Cost % of 0.34 is 85% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 5-Year Yield-on-Cost % is 0.34, which is 29% below median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.90, compared to a current price of ₹60.78 — trading 21.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.34, which is 29% below median its 10-year median of 0.48 and 85% below the Drug Manufacturers industry median of 2.27. Morepen Laboratories' overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 5-Year Yield-on-Cost % is 0.34 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹60.78 is trading 21.8% above its estimated GF Value™ of ₹49.90.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
5-Year Yield-on-Cost %: 0.34 (29% below median its 10-year median of 0.48)
GF Value™: ₹49.90 vs. price of ₹60.78 (21.8% above fair value)
Industry Position: 85% below the Drug Manufacturers median (#456 of 518)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
79GF Score
Get the complete analysis for NSE:MOREPENLAB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 